Reversing incurable cause for blindness

Macular degeneration: Gene therapy restores vision

Macular degeneration is one of the major reasons for visual impairment, round the globe, close to 200 million people are affected. It damages the photoreceptors in the retina, which lose their sensitivity to light. This can lead to impaired vision or even complete blindness.

Scientists at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) together with colleagues from the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen have developed a completely new therapeutic approach based on gene therapy. They managed to activate degenerated photoreceptors using near-infrared light.

The researchers published their findings in the journal Science.

Recommended article

Photo

Macular degeneration

Deteriorating eyesight is part of getting older? Don't be so sure

Many people accept deteriorating eyesight as an inevitable part of getting older, but blurry or distorted vision – such as when straight lines appear wavy – could be signs of age-related macular degeneration. The condition is the most common cause of severe vision loss in people age 50 and older in developed countries.

The main cause of blindness in industrialized countries is the degeneration of photoreceptors, including age-related macular degeneration and retinitis pigmentosa. During the progression of degenerative photoreceptor diseases, light-sensitive and light-insensitive photoreceptor regions in the retina coexist. For example, macular degeneration patients lose vision in the central portion of their retina but retain peripheral eyesight.

Photo
Three-component system: Antibodies (blue), gold nanorod (gold) and heat-sensitive channel (structure in the membrane; below the antibody-gold nanorod-conjugate).

Image source: Dasha Nelidova / Institute of Clinical and Molecular Ophthalamogy Basel (IOB)

Scientists have now succeeded in developing a new therapeutic approach to restore light sensitivity in degenerating retina without negatively affecting remaining vision. They were inspired by species found in nature, such as bats and snakes, that can localize near-infrared light emitted by the bodies of their preys. This is done by using heat-sensitive ion channels which are able to detect the heat of the near-infrared light. This enables the bats and snakes to superimpose thermal and visual images in the brain and thus react to their environment with greater precision. To equip retinal photoreceptors with near-infrared sensitivity, the researchers devised a three-component system. The first component contains engineered DNA that ensures that the gene coding for the heat-sensitive channel is only expressed in photoreceptors. The second component is a gold nanorod, a small particle, that efficiently absorbs near-infrared light. The third component is an antibody that ensures strong binding between the heat-sensitive channel expressed in photoreceptors and the gold nanorods that locally capture near-infrared light and locally release heat.

We believe that near-infrared stimulation is an important step towards providing useful vision to blind patients so that they can regain their ability to read or see faces

Daniel Hillier

The researchers first tested their system in engineered mice with retinal degeneration, confirming that near-infrared light effectively excites photoreceptors and that this signal is transmitted to retinal ganglion cells, the latter representing the output of the retina towards higher visual centers in the brain. Next, they showed that stimulating the mouse eye with near-infrared light is also picked up by neurons in a brain area that is important for conscious vision, the primary visual cortex. They also designed a behavioral test in which untreated blind mice were not able to use near-infrared stimulation to learn a simple task whereas blind mice treated with the three-component system could perform the task related to near-infrared stimulus.

portrait of daniel hillier
Dr. Daniel Hillier is head of the junior research group Visual Circuits and Repair at the German Primate Center in Göttingen.

Photo: Karin Tilch

In collaboration with Arnold Szabo, a co-author of the paper and Assistant Professor at the Semmelweis University in Hungary, the researchers could test their new approach on human retinas that can be kept alive in culture medium for months, though blindness sets in a day or so after death by photoreceptors losing their ability to detect light. Experimental results showed that following treatment with the three-component gene therapy method, near-infrared light exposures reactivated the human retina's visual circuitry. "We believe that near-infrared stimulation is an important step towards providing useful vision to blind patients so that they can regain their ability to read or see faces", says Daniel Hillier, head of the junior research group Visual Circuits and Repair at DPZ, and adds: "We want to give hope to blind people with these findings and will further intensify our research activities in this area here at DPZ within our main project, which focuses on the restoration of vision.”


Source: German Primate Center (DPZ) - Leibniz Institute for Primate Research

07.06.2020

Read all latest stories

Related articles

Photo

Blood coagulation

Treating hemophilia with gene therapy

Within the framework of an international study, Lund University and Skåne University Hospital have started treating patients with hemophilia with gene therapy, something that began in January this…

Photo

CRISPR

New genetic weapons challenge sickle cell disease

Help for patients with sickle cell disease may soon come from gene editing to fix the mutation that causes the disease and boost the patient's own protective fetal hemoglobin.

Photo

Ornithine Transcarbamylase deficiency

OTC deficiency: First patient benefits from gene therapy trial

A patient at the Queen Elizabeth Hospital Birmingham (QEHB) was the first person in the world to take part in a pioneering gene therapy trial for Ornithine Transcarbamylase (OTC) deficiency, a rare…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
Eppendorf – BioSpectrometer fluroescence

Research Use Only (RUO)

Eppendorf – BioSpectrometer fluroescence

Eppendorf AG
Eppendorf – μCuvette G1.0

Research Use Only (RUO)

Eppendorf – μCuvette G1.0

Eppendorf AG
Orion Diagnostica Oy – Orion GenRead

Amplification

Orion Diagnostica Oy – Orion GenRead

Orion Diagnostics Oy